Puma Biotechnology Company Top Insiders
PBYI Stock | USD 3.39 0.16 4.95% |
Puma Biotechnology's insiders are aggressively selling. The analysis of the overall insider sentiment regarding Puma Biotechnology suggests that almost all insiders are panicking. Puma Biotechnology employs about 185 people. The company is managed by 7 executives with a total tenure of roughly 27 years, averaging almost 3.0 years of service per executive, having 26.43 employees per reported executive.
Alan Auerbach Chairman Founder, Chairman, CEO and President Secretary and Member of Stock Option Committee |
Puma Biotechnology's Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
2024-08-12 | Michael Patrick Miller | Disposed 23358 @ 3.49 | View | ||
2024-07-17 | Maximo F Nougues | Disposed 4156 @ 3.7 | View | ||
2024-07-02 | Maximo F Nougues | Disposed 5295 @ 3.27 | View | ||
2024-06-13 | Troy Edward Wilson | Disposed 27000 @ 3.33 | View | ||
2024-01-03 | Maximo F Nougues | Disposed 15682 @ 4.49 | View |
Monitoring Puma Biotechnology's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Puma |
Puma Biotechnology's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Puma Biotechnology's future performance. Based on our forecasts, it is anticipated that Puma will maintain a workforce of under 190 employees by January 2025.Puma Biotechnology Management Team Effectiveness
The company has return on total asset (ROA) of 0.0973 % which means that it generated a profit of $0.0973 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.4232 %, meaning that it created $0.4232 on every $100 dollars invested by stockholders. Puma Biotechnology's management efficiency ratios could be used to measure how well Puma Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. The Puma Biotechnology's current Return On Tangible Assets is estimated to increase to 0.13. The Puma Biotechnology's current Return On Capital Employed is estimated to increase to 0.26. As of now, Puma Biotechnology's Return On Assets are increasing as compared to previous years.The Puma Biotechnology's current Net Income Applicable To Common Shares is estimated to increase to 2,415, while Common Stock Shares Outstanding is projected to decrease to under 32.7 M.
Puma Biotechnology Workforce Comparison
Puma Biotechnology is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 7,472. Puma Biotechnology holds roughly 185 in number of employees claiming about 2.48% of equities under Health Care industry.
Puma Biotechnology Profit Margins
The company has Profit Margin (PM) of 0.1 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.27 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.27.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.88 | 0.734 |
|
|
Puma Biotechnology Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Puma Biotechnology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Puma Biotechnology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Puma Biotechnology insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-06-01 | 1.4 | 7 | 5 | 189,000 | 96,900 |
2024-03-01 | 2.4 | 12 | 5 | 760,378 | 86,125 |
2023-06-01 | 1.0 | 7 | 7 | 189,000 | 109,669 |
2023-03-01 | 2.0 | 10 | 5 | 1,000,327 | 51,993 |
2022-12-01 | 0.1 | 1 | 10 | 568,181 | 6,047 |
2022-09-01 | 0.1538 | 2 | 13 | 200,000 | 82,499 |
2022-06-01 | 0.4286 | 6 | 14 | 162,000 | 97,623 |
2022-03-01 | 1.0909 | 12 | 11 | 2,688,409 | 68,403 |
2021-09-01 | 0.1111 | 1 | 9 | 108,721 | 11,182 |
2021-06-01 | 0.2917 | 7 | 24 | 257,148 | 164,641 |
2021-03-01 | 1.0833 | 13 | 12 | 839,864 | 37,855 |
2020-09-01 | 0.125 | 1 | 8 | 93,953 | 14,395 |
2020-06-01 | 0.7 | 7 | 10 | 180,236 | 46,262 |
2020-03-01 | 1.0 | 10 | 10 | 841,061 | 11,569 |
2019-12-01 | 0.2857 | 2 | 7 | 210,507 | 1,699 |
2019-09-01 | 0.0909 | 1 | 11 | 4,500 | 19,933 |
2019-06-01 | 0.8333 | 5 | 6 | 97,115 | 1,712 |
2019-03-01 | 0.5833 | 7 | 12 | 188,749 | 21,560 |
2018-12-01 | 1.0 | 1 | 1 | 90,000 | 1,239 |
2018-06-01 | 5.0 | 5 | 1 | 28,770 | 1,211 |
2018-03-01 | 2.0 | 10 | 5 | 279,885 | 24,079 |
2017-09-01 | 0.2857 | 4 | 14 | 35,000 | 87,825 |
2017-06-01 | 0.1667 | 5 | 30 | 51,416 | 1,990,088 |
2017-03-01 | 0.625 | 5 | 8 | 180,250 | 23,145 |
2016-09-01 | 1.0 | 1 | 1 | 90,000 | 0.00 |
2015-09-01 | 4.5 | 9 | 2 | 294,500 | 6,000 |
2013-12-01 | 12.0 | 12 | 1 | 727,149 | 0.00 |
2011-12-01 | 0.5 | 2 | 4 | 166,551 | 3,000,000 |
Puma Biotechnology Notable Stakeholders
A Puma Biotechnology stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Puma Biotechnology often face trade-offs trying to please all of them. Puma Biotechnology's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Puma Biotechnology's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Alan Auerbach | Founder, Chairman, CEO and President Secretary and Member of Stock Option Committee | Profile | |
Maximo Nougues | CFO Officer | Profile | |
Mariann Ohanesian | Senior Director, Investor Relations | Profile | |
Jeffrey Ludwig | Chief Officer | Profile | |
Alvin Pharmd | Chief Officer | Profile | |
FRAPS BSc | Pharmacovigilance, Affairs | Profile | |
Bo Chao | Senior Development | Profile |
About Puma Biotechnology Management Performance
The success or failure of an entity such as Puma Biotechnology often depends on how effective the management is. Puma Biotechnology management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Puma management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Puma management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.13 | 0.13 | |
Return On Capital Employed | 0.25 | 0.26 | |
Return On Assets | 0.09 | 0.10 | |
Return On Equity | 0.40 | 0.42 |
Puma Biotechnology Workforce Analysis
Traditionally, organizations such as Puma Biotechnology use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Puma Biotechnology within its industry.Puma Biotechnology Manpower Efficiency
Return on Puma Biotechnology Manpower
Revenue Per Employee | 1.3M | |
Revenue Per Executive | 33.7M | |
Net Income Per Employee | 116.7K | |
Net Income Per Executive | 3.1M | |
Working Capital Per Employee | 307K | |
Working Capital Per Executive | 8.1M |
Complementary Tools for Puma Stock analysis
When running Puma Biotechnology's price analysis, check to measure Puma Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Puma Biotechnology is operating at the current time. Most of Puma Biotechnology's value examination focuses on studying past and present price action to predict the probability of Puma Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Puma Biotechnology's price. Additionally, you may evaluate how the addition of Puma Biotechnology to your portfolios can decrease your overall portfolio volatility.
Global Correlations Find global opportunities by holding instruments from different markets | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
CEOs Directory Screen CEOs from public companies around the world | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Fundamental Analysis View fundamental data based on most recent published financial statements |